At ASCO 2025, Bayer announced new data from recent clinical trials that highlight significant advancements in both prostate ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

Skyhawk recently started dosing patients in its phase 2/3 FALCON-HD trial of lead candidate SKY-0515, involving patients with ...

The convergence of behavioural health and movement disorder assessment technologies represents just the beginning of a ...

Along with plenty of initiatives in areas like food and exposure to chemicals like pesticides, the document (PDF), acquired ...

Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

Adding Nykode Therapeutics' VB10.16 vaccine to treatment with Roche's cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer.

EVERSANA has launched a new pharmacovigilance platform to answer the need for advanced analytics and AI in drug safety monitoring and risk management.

The UK life sciences raised £1.23bn in venture capital investment in the first half of 2025, although there was a fallback in the second quarter.

Boehringer Ingelheim is preparing for multiple drug launches in the second half of 2025, following strong first-half financial results that saw the company report a 6.3% rise in group net sales to ...